Literature DB >> 10529450

Neuroprotective effect of high-dose albumin therapy against global ischemic brain injury in rats.

L Belayev1, I Saul, P W Huh, N Finotti, W Zhao, R Busto, M D Ginsberg.   

Abstract

The purpose of this study was to determine whether treatment with high-dose human serum albumin (HSA) would offer protection in a model of high-grade transient forebrain ischemia. Twenty-six fasted Wistar rats underwent bilateral common carotid artery occlusion and severe hypotension (50 mmHg) for 10 min. The agent (25% HSA) or vehicle (0.9% NaCl) was administered i.v. 5 min after termination of ischemia. HSA-treated rats showed significantly improved neurological deficits throughout a 7-day survival period. Histologically, HSA-treated rats showed 2.4- to 5.3-fold increases in numbers of surviving CA1 hippocampal pyramidal neurons compared to saline-treated animals. These results document that high-dose albumin therapy instituted 5 min after global ischemia significantly improves neurological score and reduces histological damage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529450     DOI: 10.1016/s0006-8993(99)01952-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  21 in total

1.  Treatment of subarachnoid hemorrhage with human albumin: ALISAH study. Rationale and design.

Authors:  Jose I Suarez; Renee H Martin
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

Review 2.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

Review 3.  Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials.

Authors:  Jialing Liu; Yongting Wang; Yosuke Akamatsu; Chih Cheng Lee; R Anne Stetler; Michael T Lawton; Guo-Yuan Yang
Journal:  Prog Neurobiol       Date:  2013-11-27       Impact factor: 11.685

4.  High dose human serum albumin for the treatment of acute ischemic stroke: a safety study.

Authors:  Sebastian Koch; Mauricio Concha; Tarek Wazzan; Jose G Romano; Alejandro Forteza
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

5.  The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2.

Authors:  Myron D Ginsberg; Yuko Y Palesch; Renee H Martin; Michael D Hill; Claudia S Moy; Bonnie D Waldman; Sharon D Yeatts; Diego Tamariz; Karla Ryckborst
Journal:  Stroke       Date:  2010-12-16       Impact factor: 7.914

6.  Pharmacological treatment of delayed cerebral ischemia and vasospasm in subarachnoid hemorrhage.

Authors:  Diego Castanares-Zapatero; Philippe Hantson
Journal:  Ann Intensive Care       Date:  2011-05-24       Impact factor: 6.925

7.  Albumin therapy in acute stroke patients.

Authors:  Dong Hoon Shin; Gyeong Joon Moon; Oh Young Bang
Journal:  J Neurol       Date:  2007-04-13       Impact factor: 4.849

8.  Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways.

Authors:  Hantamalala Ralay Ranaivo; Mark S Wainwright
Journal:  Brain Res       Date:  2009-12-02       Impact factor: 3.252

9.  EGF amplifies the replacement of parvalbumin-expressing striatal interneurons after ischemia.

Authors:  Tetsuyuki Teramoto; Jianhua Qiu; Jean-Christophe Plumier; Michael A Moskowitz
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

10.  Docosahexaenoic acid complexed to albumin provides neuroprotection after experimental stroke in aged rats.

Authors:  Tiffany N Eady; Larissa Khoutorova; Andre Obenaus; Alena Mohd-Yusof; Nicolas G Bazan; Ludmila Belayev
Journal:  Neurobiol Dis       Date:  2013-09-21       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.